Edward Faber is an Oncology physician affiliated with Oncology Hematology Care. OpenAlex indexes 80 publications with 977 citations (h-index 13).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4777 E Galbraith Rd
Ste 320
Cincinnati, OH 452362725
Telephone
513-751-2273Provider last certified this registry record 22 Apr 2021.
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Scientific Affairs, LLCProgram year20251 payment
- Legend Biotech USA Inc.Program year20252 payments
- Janssen Biotech, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
30.7%Thalidomide Analog23.2%Lenalidomide49%Pomalyst28%Revlimid23%Part D<11 patientsKinase inhibitor4.2%Sprycel100%Part D<11 patients+ 1 more class in this area
Dermatology
23.6%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor23.6%Acyclovir100%Part D≥30 patientsAnti-infectives
11.3%Short-acting sulfonamides5.8%Sulfamethoxazole-Trimethoprim100%Part D<11 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor3.1%Valacyclovir100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Current experiences with teclistamab in patients with multiple myeloma and renal impairment
Expert Review of Hematology
2025 - A Phase 1 Study of P-BCMA-ALLO1, a Non-Viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM): Results from Optimized Lymphodepletion Cohort (Arm C)
Biology of Blood and Marrow Transplantation
2025 - OA-04 A Phase 1 Study of P-BCMA- ALLO1, a Non-viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM)
Clinical Lymphoma Myeloma & Leukemia
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Jamie Waselenko, MD
Oncology Hematology Care
Bernard Hertzman, MD
Oncology Hematology Care
Akash Mukherjee, MD
Oncology Hematology Care
David Drosick, MD
Oncology Hematology Care
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”